HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MPLT

MapLight Therapeutics Inc

Last Close
May 29  •  04:00PM ET
29.31
Dollar change
-0.47
Percentage change
-1.58 %
Healthcare • Biotechnology • USA • Small • NASD
Peers: ACAD AXSM KYMR NUVL BMRN RYTM INCY KRYS MDGL NBIX
 | Held by: VTI IWM VXF VTWO SCHA IWO IWN IWC JSML TMSL
Scroll to Statements
Index
RUT
P/E
-
EPS (ttm)
-4.52
Insider Own
82.34%
Shs Outstand
45.21M
Perf Week
0.10%
Market Cap
1.25B
Forward P/E
-
EPS next Y
-4.36
Insider Trans
-1.70%
Shs Float
7.53M
Perf Month
-3.24%
Enterprise Value
944.62M
PEG
-
EPS next Q
-1.25
Inst Own
30.29%
Short Float
18.07%
Perf Quarter
69.72%
Income
-199.48M
P/S
-
EPS this Y
74.00%
Inst Trans
4.75%
Short Ratio
4.99
Perf Half Y
128.81%
Sales
0.00M
P/B
3.31
EPS next Y
9.55%
ROA
-75.23%
Short Interest
1.36M
Perf YTD
66.87%
Book/sh
8.84
P/C
4.03
EPS next 5Y
37.63%
ROE
-80.95%
52W High
33.28 -11.93%
Perf Year
-
Cash/sh
7.28
P/FCF
-
EPS past 3/5Y
-71.59% -
ROIC
-49.31%
52W Low
12.24 139.46%
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
5.59% 8.13%
Perf 5Y
-
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-
Oper. Margin
-
ATR (14)
2.19
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
22.91
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
53.73
Recom
1.00
Dividend Gr. 3/5Y
- -
Current Ratio
22.91
EPS Q/Q
-148.89%
SMA20
1.16%
Beta
-
Target Price
37.90
Payout
-
Debt/Eq
0.01
Sales Q/Q
-
SMA50
10.89%
Rel Volume
1.60
Prev Close
29.78
Employees
133
LT Debt/Eq
0.01
Earnings
May 14 AMC
SMA200
43.67%
Avg Volume
272.66K
Price
29.31
IPO
Oct 27, 2025
Option/Short
Yes / Yes
EPS/Sales Surpr.
-27.89% -
Trades
Volume
436,845
Change
-1.58%
Date Action Analyst Rating Change Price Target Change
May-27-26Initiated UBS Buy $48
May-21-26Initiated Craig Hallum Buy $43
May-04-26Initiated H.C. Wainwright Buy $45
Apr-08-26Initiated Needham Buy $37
Apr-07-26Initiated TD Cowen Buy
Mar-19-26Initiated Canaccord Genuity Buy $35
Nov-21-25Initiated Stifel Buy $28
Nov-21-25Initiated Morgan Stanley Overweight $34
Nov-21-25Initiated Leerink Partners Outperform $30
Nov-21-25Initiated Jefferies Buy $32
May-14-26 04:05PM
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
(GlobeNewswire)
May-08-26 07:00AM
MapLight Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire) -6.16%
May-01-26 07:00AM
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
(GlobeNewswire)
Mar-26-26 07:00AM
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
(GlobeNewswire) +6.01%
Mar-02-26 07:00AM
MapLight Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
07:00AM Loading…
Jan-09-26 07:00AM
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
(GlobeNewswire)
Jan-05-26 07:00AM
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
(GlobeNewswire)
Dec-16-25 07:00AM
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
(GlobeNewswire)
Dec-04-25 07:00AM
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
(GlobeNewswire) +8.39%
Nov-07-25 07:26PM
MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors
(Barrons.com)
Oct-29-25 09:06AM
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
(GlobeNewswire)
Oct-26-25 05:30PM
MapLight Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
M.D.Dr. Christopher A. Kroeger M.B.A.
Ph.D.Dr. Robert C. Malenka M.D.
Chief Financial OfficerMr. Vishwas Setia
Ph.D.Dr. Erin Pennock Foff M.D.
FounderDr. Karoly Nikolich Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kroeger Christopher A.Chief Executive OfficerMay 18 '26Sale27.19118,2353,215,0001,394,094May 18 09:27 PM
Hanson KristopherGeneral CounselMay 11 '26Sale30.1313,917419,263162,331May 11 09:30 PM
Kroeger Christopher A.Chief Executive OfficerMay 08 '26Sale27.6934,411952,8351,526,309May 11 09:30 PM
Kroeger Christopher A.Chief Executive OfficerMay 07 '26Sale28.6520,100575,7971,560,720May 11 09:30 PM
Kroeger Christopher A.Chief Executive OfficerMay 11 '26Sale30.1113,980421,0021,512,329May 11 09:30 PM
Foff Erin PennockChief Medical OfficerMay 07 '26Sale28.544,438126,640346,059May 11 09:30 PM
Lillie James WoodruffChief Scientific OfficerMay 07 '26Sale28.2872120,390242,729May 11 09:30 PM
Setia VishwasChief Financial OfficerMay 04 '26Sale28.1114,904418,930377,723May 06 08:15 PM
Setia VishwasChief Financial OfficerMay 05 '26Sale28.2010,903307,444366,820May 06 08:15 PM
Setia VishwasChief Financial OfficerMay 06 '26Sale28.2410,564298,345356,256May 06 08:15 PM
Foff Erin PennockChief Medical OfficerMay 06 '26Sale28.7624,052691,749350,497May 06 08:15 PM
Foff Erin PennockChief Medical OfficerMay 04 '26Sale27.9615,652437,629385,125May 06 08:15 PM
Foff Erin PennockChief Medical OfficerMay 05 '26Sale28.2010,576298,216374,549May 06 08:15 PM
Lillie James WoodruffChief Scientific OfficerMay 06 '26Sale28.7624,811713,599243,450May 06 08:15 PM
Lillie James WoodruffChief Scientific OfficerMay 04 '26Sale27.9615,801441,813279,356May 06 08:15 PM
Lillie James WoodruffChief Scientific OfficerMay 05 '26Sale28.2011,095312,839268,261May 06 08:15 PM
Hanson KristopherGeneral CounselMay 04 '26Sale27.8913,917388,177176,248May 06 08:15 PM
Kroeger Christopher A.Chief Executive OfficerMay 06 '26Sale28.7623,701681,5831,580,820May 06 08:15 PM
Kroeger Christopher A.Chief Executive OfficerMay 04 '26Sale27.9615,571435,3631,614,993May 06 08:15 PM
Kroeger Christopher A.Chief Executive OfficerMay 05 '26Sale28.2010,472295,2891,604,521May 06 08:15 PM
Kroeger Christopher A.OfficerMay 04 '26Proposed Sale30.70236,4707,259,629May 04 05:47 PM
Setia VishwasOfficerMay 04 '26Proposed Sale30.7036,3711,116,590May 04 05:28 PM
Foff Erin PennockOfficerMay 04 '26Proposed Sale30.7054,7181,679,843May 04 05:22 PM
Lillie James WoodruffOfficerMay 04 '26Proposed Sale30.7052,4281,609,540May 04 05:20 PM
Hanson KristopherOfficerMay 04 '26Proposed Sale30.7027,834854,504May 04 05:18 PM
GILLIS JONATHANCAAO and PAOApr 27 '26Sale29.7451,9001,543,369199,154Apr 29 04:30 PM
GILLIS JONATHANCAAO and PAOApr 28 '26Sale30.3517,935544,319181,219Apr 29 04:30 PM
Kreitzer AnatolChief Discovery OfficerApr 27 '26Sale29.6645,4221,347,066211,190Apr 29 04:30 PM
ANATOL KREITZEROfficerApr 27 '26Proposed Sale29.7645,4221,351,759Apr 27 04:34 PM
JONATHAN GILLISOfficerApr 27 '26Proposed Sale29.7669,8352,078,290Apr 27 04:32 PM
Kreitzer AnatolChief Discovery OfficerApr 15 '26Sale26.613,31688,239256,612Apr 17 04:05 PM
GILLIS JONATHANCAAO and PAOApr 15 '26Sale26.613,59095,530251,054Apr 17 04:05 PM
Hanson KristopherGeneral CounselApr 15 '26Sale26.801,52940,977190,463Apr 17 04:05 PM
Hanson KristopherGeneral CounselApr 16 '26Sale27.372988,157190,165Apr 17 04:05 PM
Setia VishwasChief Financial OfficerApr 15 '26Sale26.872,80675,397392,743Apr 17 04:05 PM
Setia VishwasChief Financial OfficerApr 16 '26Sale27.371163,175392,627Apr 17 04:05 PM
Lillie James WoodruffChief Scientific OfficerApr 16 '26Sale27.372,78376,175295,157Apr 17 04:05 PM
Lillie James WoodruffChief Scientific OfficerApr 15 '26Sale26.821,73046,399297,940Apr 17 04:05 PM
Foff Erin PennockChief Medical OfficerApr 15 '26Sale26.842,04454,861401,946Apr 17 04:05 PM
Foff Erin PennockChief Medical OfficerApr 16 '26Sale27.371,16931,998400,777Apr 17 04:05 PM
Kroeger Christopher A.Chief Executive OfficerApr 16 '26Sale27.3710,052275,1411,630,564Apr 17 04:05 PM
Kroeger Christopher A.Chief Executive OfficerApr 15 '26Sale26.939,135246,0061,640,616Apr 17 04:05 PM
Malenka Robert C.DirectorApr 15 '26Sale26.908,593231,152316,466Apr 17 04:05 PM
Anatol KreitzerOfficerApr 15 '26Proposed Sale27.025,000135,100Apr 15 05:20 PM
Jonathan GillisOfficerApr 15 '26Proposed Sale27.024,000108,080Apr 15 05:15 PM
ROBERT MALENKADirectorApr 15 '26Proposed Sale27.028,593232,183Apr 15 04:47 PM
Kroeger Christopher A.OfficerApr 15 '26Proposed Sale27.0220,822562,610Apr 15 04:28 PM
Setia VishwasOfficerApr 15 '26Proposed Sale27.022,99080,799Apr 15 04:17 PM
Lillie James WoodruffOfficerApr 15 '26Proposed Sale27.024,896132,290Apr 15 04:14 PM
Hanson KristopherOfficerApr 15 '26Proposed Sale27.021,82749,366Apr 15 04:11 PM
Foff Erin PennockOfficerApr 15 '26Proposed Sale27.023,47293,813Apr 15 04:06 PM
Malenka Robert C.DirectorFeb 23 '26Sale18.4211,264207,464325,795Feb 24 06:57 PM
Malenka Robert C.DirectorFeb 20 '26Sale18.032,19539,576337,059Feb 24 06:57 PM
Malenka Robert C.DirectorFeb 24 '26Sale18.1573613,358325,059Feb 24 06:57 PM
ROBERT MALENKADirectorFeb 24 '26Proposed Sale18.1473613,355Feb 24 04:36 PM
ROBERT MALENKADirectorFeb 23 '26Proposed Sale18.4211,264207,491Feb 23 04:33 PM
Pavlov GeorgeDirectorFeb 18 '26Buy17.4810,658186,30210,658Feb 20 06:25 PM
Pavlov GeorgeDirectorFeb 20 '26Buy17.869,920177,17125,000Feb 20 06:25 PM
Pavlov GeorgeDirectorFeb 19 '26Buy17.574,42277,69515,080Feb 20 06:25 PM
ROBERT MALENKADirectorFeb 20 '26Proposed Sale18.032,19539,577Feb 20 04:16 PM
Malenka Robert C.DirectorFeb 13 '26Sale18.2112,116220,632339,254Feb 18 07:33 PM
ROBERT MALENKADirectorFeb 13 '26Proposed Sale18.2112,116220,686Feb 13 04:08 PM
Garnett Timothy JohnDirectorFeb 10 '26Buy17.8914,124252,67814,124Feb 12 05:45 PM
Malenka Robert C.DirectorFeb 10 '26Sale18.126,622119,991351,611Feb 12 05:45 PM
Malenka Robert C.DirectorFeb 11 '26Sale18.002414,338351,370Feb 12 05:45 PM
ROBERT MALENKADirectorFeb 11 '26Proposed Sale18.002414,338Feb 11 04:13 PM
ROBERT MALENKADirectorFeb 10 '26Proposed Sale18.126,622119,963Feb 10 04:22 PM
Malenka Robert C.DirectorFeb 02 '26Sale18.027,039126,843358,234Feb 04 09:15 PM
Malenka Robert C.DirectorFeb 03 '26Sale18.00118358,233Feb 04 09:15 PM
ROBERT MALENKADirectorFeb 03 '26Proposed Sale18.00118Feb 03 04:15 PM
ROBERT MALENKADirectorFeb 02 '26Proposed Sale18.027,039126,835Feb 02 04:37 PM
Malenka Robert C.DirectorJan 29 '26Sale18.5521,262394,410371,885Jan 30 08:50 PM
Malenka Robert C.DirectorJan 28 '26Sale18.656,524121,704393,147Jan 30 08:50 PM
Malenka Robert C.DirectorJan 30 '26Sale18.116,612119,743365,273Jan 30 08:50 PM
ROBERT MALENKADirectorJan 30 '26Proposed Sale18.116,612119,737Jan 30 04:17 PM
ROBERT MALENKADirectorJan 29 '26Proposed Sale18.5521,262394,470Jan 29 04:06 PM
ROBERT MALENKADirectorJan 28 '26Proposed Sale18.656,524121,690Jan 28 04:20 PM
Novo Holdings A/S10% OwnerOct 28 '25Buy17.00952,94116,199,9973,686,622Oct 30 04:31 PM
Catalyst4, Inc.10% OwnerOct 28 '25Buy17.005,441,17692,499,99219,697,464Oct 29 04:16 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)